Imugene Limited

Equities

IMU

AU000000IMU9

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 02:10:46 2024-04-30 am EDT			5-day change	1st Jan Change
0.087 ^AUD	+6.10%		+2.35%	-20.91%

Apr. 16	Imugene Signs Deal to Sell Manufacturing Facility For $6 Million	MT
Apr. 16	Kincell Bio, LLC signed an asset purchase agreement to acquire North Carolina manufacturing facility from Imugene Limited for $6 million.	CI

Imugene : New Edison Research Note Published

July 12, 2015 at 09:28 pm EDT

13 July 2015

ASX RELEASE Publication of Research Note

Imugene Limited

ACN 009 179 551

Suite 1, 1233 High Street

Armadale VIC 3142

New Research Note available from Edison Investment Research

Imugene Limited (ASX:IMU) is pleased to advise that a new Research Note compiled by Edison Investment Research titled "Imugene -‐ HER-‐Vaxx antibodies outperform Herceptin" is now available from the company.

To view the Research Note, please follow the link below or copy and paste the link to your web browser:

http://www.imugene.com/investor-center/analyst-coverage

Ends Charles Walker Managing Director Tel: +61 (0) 4 5044 6990 cwalker@imugene.comwww.imugene.com

IMUGENE LIMITED Telephone +61 3 9824 5254 Fax +61 3 9822 7735 Website www.imugene.com

distributed by

Latest news about Imugene Limited

Imugene Signs Deal to Sell Manufacturing Facility For $6 Million	Apr. 16	MT
Kincell Bio, LLC signed an asset purchase agreement to acquire North Carolina manufacturing facility from Imugene Limited for $6 million.	Apr. 15	CI
Imugene Limited Announce Enrolment Opened for Its Expansion Study in Bile Tract Cancer (Cholangiocarcinoma) Patients	Apr. 15	CI
Imugene Commences Enrolment for Cholangiocarcinoma Expansion Study	Apr. 14	MT
Imugene Secures Patent for Oncolytic Virotherapy CF33 in China	Apr. 03	MT
Arovella Therapeutics' ALA-101-onCARlytics Collaboration with Imugene Ends; Shares Down 12%	Mar. 19	MT
Imugene Limited Announces Phase 1 onCARlytics Solid Tumour Trial Advances to Combination Arm Treatment	Mar. 11	CI
Imugene's Phase 1 onCARlytics Trial to Commence Combination Arm Treatment	Mar. 10	MT
Imugene Widens Per-Share Loss in H1 FY24 to AU$0.01 on Higher General, R&D Spending	Feb. 28	MT
Imugene Reports H1 FY24 Loss Widens as Expenses Grow	Feb. 28	MT
Imugene Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 28	CI
Imugene’s Phase 1 onCARlytics Trial Doses First Patient in Intravenous Monotherapy Arm	Feb. 14	MT
Esken's Southend Airport faces further allegations	Jan. 23	AN
MaxCyte Inks Platform License Deal With Cancer Medicine Developer Imugene	Jan. 23	MT
Australian Shares End Five-Day Losing Streak Amid Market Conviction of Early US Fed Pivot	Jan. 19	MT
Imugene’s VAXINIA Metastatic Advanced Solid Tumors Trial Doses First Patients in Higher Dose Cohorts; Shares Up 10%	Jan. 18	MT
Imugene's Vaxinia Trial Shows Positive Signs	Jan. 18	MT
Imugene to Open Phase Two Colorectal Cancer Trial in the UK, Australia	Dec. 06	MT
Imugene to Secure European Patent for Cancer Vaccine	Dec. 05	MT
FDA Grants Fast Track Designation for Imugene's CF33-hNIS in Bile Duct Cancer MAST Program	Nov. 28	MT
US FDA Transfers Cancer Medication Application to Imugene	23-09-28	MT
Imugene Raises AU$18 Million in Share Purchase Plan	23-09-25	MT
Imugene Limited(ASX:IMU) dropped from S&P/ASX 200 Index	23-09-18	CI
Imugene Appoints Medical Chief	23-09-04	MT
Imugene Limited Appoints Paul Woodard as Chief Medical Officer	23-09-03	CI

Chart Imugene Limited

Duration

Period

More charts

Company Profile

Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the bodyâs immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs.

Sector

Biotechnology & Medical Research

Calendar

2024-08-29 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.082 AUD

Average target price

0.3533 AUD

Spread / Average Target

+330.89%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IMUGENE LIMITED	-20.91%	394M
IQVIA HOLDINGS INC.	+1.28%	42.86B
MODERNA, INC.	+11.60%	42.74B
LONZA GROUP AG	+45.21%	41.36B
CELLTRION, INC.	-8.83%	27.68B
ICON PUBLIC LIMITED COMPANY	+7.72%	25.15B
ALNYLAM PHARMACEUTICALS, INC.	-23.26%	18.63B
MEDPACE HOLDINGS, INC.	+29.69%	12.37B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.27%	11.92B
UNITED THERAPEUTICS CORPORATION	+7.57%	11.21B

Other Biotechnology & Medical Research